Dimensional Fund Advisors LP increased its stake in Affimed NV (NASDAQ:AFMD) by 817.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 137,783 shares of the biopharmaceutical company’s stock after purchasing an additional 122,773 shares during the period. Dimensional Fund Advisors LP owned 0.31% of Affimed worth $310,000 as of its most recent filing with the Securities & Exchange Commission.
Separately, Nationwide Fund Advisors increased its holdings in shares of Affimed by 4.6% during the 2nd quarter. Nationwide Fund Advisors now owns 506,199 shares of the biopharmaceutical company’s stock valued at $1,038,000 after purchasing an additional 22,172 shares in the last quarter. 38.89% of the stock is owned by institutional investors.
Affimed NV (AFMD) remained flat at $$2.20 during trading on Tuesday. The company’s stock had a trading volume of 1,125,100 shares, compared to its average volume of 1,037,270. The company has a current ratio of 6.43, a quick ratio of 6.39 and a debt-to-equity ratio of 0.14. Affimed NV has a 1-year low of $1.15 and a 1-year high of $2.95.
Separately, Oppenheimer reissued a “hold” rating on shares of Affimed in a report on Friday, November 24th.
TRADEMARK VIOLATION WARNING: This report was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/02/20/affimed-nv-afmd-shares-bought-by-dimensional-fund-advisors-lp.html.
Affimed Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.